drugset / Trial / NCT04589832
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Phase 1/2
Terminated
6 enrolled
Arkadiusz Z. Dudek, MD
Genentech, Inc. · collabHealthPartners Institute Regions Cancer Care Center · collabMidwest Melanoma Partnership · collabVanquish Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO) will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after every 2 cycles. Treatment will continue until disease progression based on RECIST criteria or intolerable toxicity.
Timeline
- Start
- 2021-01-11
- Primary completion
- 2022-03-22
- Completion
- 2022-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entrectinib | Small molecule | — | Oral |
| Subject | PAC-1 | Small molecule | — | Oral |